Vaxcyte Stock Today
| PCVX Stock | USD 93.98 2.53 2.77% |
Performance5 of 100
| Odds Of DistressLess than 28
|
Vaxcyte is trading at 93.98 as of the 28th of November 2024; that is 2.77 percent increase since the beginning of the trading day. The stock's open price was 91.45. Vaxcyte has about a 28 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Vaxcyte are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of June 2020 | Category Healthcare | Classification Health Care |
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. Vaxcyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 124.64 M outstanding shares of which 8.93 M shares are at this time shorted by private and institutional investors with about 7.66 trading days to cover. More on Vaxcyte
Moving against Vaxcyte Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Vaxcyte Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CFO | Andrew MBA | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsVaxcyte can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vaxcyte's financial leverage. It provides some insight into what part of Vaxcyte's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Vaxcyte (PCVX) is traded on NASDAQ Exchange in USA. It is located in 825 Industrial Road, San Carlos, CA, United States, 94070 and employs 254 people. Vaxcyte is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 11.4 B. Vaxcyte conducts business under Biotechnology sector and is part of Health Care industry. The entity has 124.64 M outstanding shares of which 8.93 M shares are at this time shorted by private and institutional investors with about 7.66 trading days to cover.
Vaxcyte currently holds about 354.5 M in cash with (296.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.98.
Check Vaxcyte Probability Of Bankruptcy
Ownership AllocationThe majority of Vaxcyte outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vaxcyte to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vaxcyte. Please pay attention to any change in the institutional holdings of Vaxcyte as this could imply that something significant has changed or is about to change at the company.
Check Vaxcyte Ownership Details
Vaxcyte Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 2.7 M | |
| Darwin Global Management, Ltd. | 2024-06-30 | 2.1 M | |
| Perceptive Advisors Llc | 2024-09-30 | 2 M | |
| Driehaus Capital Management Llc | 2024-06-30 | 1.9 M | |
| Westfield Capital Management Company, Lp | 2024-09-30 | 1.7 M | |
| Alliancebernstein L.p. | 2024-06-30 | 1.7 M | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 1.3 M | |
| Fred Alger Management, Llc | 2024-09-30 | 1.2 M | |
| Jennison Associates Llc | 2024-09-30 | 1.2 M | |
| Fmr Inc | 2024-09-30 | 15.8 M | |
| Vanguard Group Inc | 2024-09-30 | 11.4 M |
Vaxcyte Historical Income Statement
Vaxcyte Stock Against Markets
Vaxcyte Corporate Management
| Mikhail JD | General VP | Profile | |
| Karen Alderete | Ex HR | Profile | |
| Whitney Jones | Chief Officer | Profile | |
| Ashish MBA | CoFounder Officer | Profile | |
| Jeff Fairman | CoFounder Research | Profile | |
| Grant MBA | CEO CoFounder | Profile |
Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.